Clinical Trials Browser

Breast Neoplasms

Brain Neoplasms, Breast Neoplasms

Advanced Breast Cancer

Breast Cancer Metastatic

Brain Neoplasms, Glioblastoma, Neoplasm Metastasis, Meningeal Carcinomatosis

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Breast Neoplasms

Salivary Gland Neoplasms

Ovarian Neoplasms, Recurrence

Neoplasm Metastasis, Neoplasms

Stomach Neoplasms

Breast Neoplasms

HER2-positive Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Breast Cancer With Brain Metastasis

Breast Neoplasms

Breast Cancer With Brain Metastasis

Breast Neoplasms

Breast Neoplasms

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Meningeal Carcinomatosis

Breast Neoplasms

Breast Neoplasms

HER2-negative Breast Cancer

Gastric Adenocarcinoma

Esophageal Neoplasms, Stomach Neoplasms, Neoplasm, Residual

Triple Negative Breast Neoplasms

Breast Neoplasms

Clinical Trials

TRANSCENDER

TUXEDO-4

PONTIAC

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

HERCULES

ELPIS

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

STORM

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

TROY

Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers

Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

ANISE

Scalp Cooling in MBC

ADAPTHER2-IV

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

TRADE DXd

ALTER

THUNDER

ARIADNE

THUMB

DEMETHER

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

DEBBRAH

DAISY

Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer

ORIENTA

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients with HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

DECIPHER

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

TUXEDO-1